SREBP1 INDUCES RESISTANCE TO HIF-2α ANTAGONIST IN CLEAR CELL RENAL CELL CARCINOMA

被引：0
|
作者：
Son, Da Hyeon
Lee, Young Ju
Kim, Hyo Eun
Kim, Eun Song
Park, Sung Yul
Yoon, Young Eun
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD51-08
引用
收藏
页码：E1067 / E1068
页数：2
相关论文
共 50 条
  • [21] The therapeutic potential of HIF-2 antagonism in renal cell carcinoma
    Cuvillier, Olivier
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (01) : 131 - 133
  • [22] Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α
    Fan, Yang
    Li, Hongzhao
    Ma, Xin
    Gao, Yu
    Bao, Xu
    Du, Qingshan
    Ma, Minghui
    Liu, Kan
    Yao, Yuanxin
    Huang, Qingbo
    Zhang, Yu
    Zhang, Xu
    ONCOTARGET, 2016, 7 (14) : 18280 - 18294
  • [23] OGT/HIF-2α axis promotes the progression of clear cell renal cell carcinoma and regulates its sensitivity to ferroptosis
    Yang, Zhou
    Wei, Xiyi
    Ji, Chengjian
    Ren, Xiaohan
    Su, Wei
    Wang, Yichun
    Zhou, Jingwan
    Zhao, Zheng
    Zhou, Pengcheng
    Zhao, Kejie
    Yao, Bing
    Song, Ninghong
    Qin, Chao
    ISCIENCE, 2023, 26 (11)
  • [24] Targeting HIF2 in Clear Cell Renal Cell Carcinoma
    Cho, Hyejin
    Kaelin, William G.
    TARGETING CANCER, VOL 81, 2016, 2016, 81 : 113 - 121
  • [25] MED15 is upregulated by HIF-2α and promotes proliferation and metastasis in clear cell renal cell carcinoma via activation of SREBP-dependent fatty acid synthesis
    Hua, Xiaoliang
    Ge, Shengdong
    Zhang, Li
    Jiang, Qing
    Chen, Juan
    Xiao, Haibing
    Liang, Chaozhao
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [26] PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
    Wallace, Eli M.
    Cao, Zhaodan
    Cheng, Tzuling
    Czerwinski, Robert
    Dixon, Darryl D.
    Du, Xinlin
    Goggin, Barry
    Grina, Jonas
    Halfmann, Megan
    Han, Guangzhou
    Huang, Heli
    Josey, John A.
    Maddie, Melissa A.
    Olive, Sarah
    Rizzi, James
    Schlachter, Stephen T.
    Tan, Hui-Ling
    Wang, Bin
    Wang, Keshi
    Wehn, Paul M.
    Xie, Shanhai
    Xu, Rui
    Yang, Hanbiao
    CANCER RESEARCH, 2015, 75
  • [27] THE PRIMARY IRON UPTAKE RECEPTOR, TRANSFERRIN RECEPTOR 1, MEDIATES HIF-2α OVEREXPRESSION AND PROLIFERATION IN CLEAR CELL RENAL CELL CARCINOMA CELLS
    Siff, Thomas
    Greene, Christopher
    Sharma, Nikita
    Fiorica, Peter
    Menon, Arun
    Smith, Gary
    Gross, Kenneth
    Kauffman, Eric
    JOURNAL OF UROLOGY, 2019, 201 (04): : E210 - E210
  • [28] Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma
    Hoefflin, Rouven
    Harlander, Sabine
    Abhari, Behnaz A.
    Peighambari, Asin
    Adlesic, Mojca
    Seidel, Philipp
    Zodel, Kyra
    Haug, Stefan
    Goecmen, Burulca
    Li, Yong
    Lahrmann, Bernd
    Grabe, Niels
    Heide, Danijela
    Boerries, Melanie
    Koettgen, Anna
    Heikenwalder, Mathias
    Frew, Ian J.
    CANCERS, 2021, 13 (19)
  • [29] Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma
    Xiong, Ying
    Liu, Li
    Xia, Yu
    Qi, Yangyang
    Chen, Yifan
    Chen, Lingli
    Zhang, Peipei
    Kong, Yunyi
    Qu, Yang
    Wang, Zewei
    Lin, Zhiyuan
    Chen, Xiang
    Xiang, Zhuoyi
    Wang, Jiajun
    Bai, Qi
    Zhang, Weijuan
    Yang, Yuanfeng
    Guo, Jianming
    Xu, Jiejie
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (05) : 731 - 741
  • [30] Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma
    Ying Xiong
    Li Liu
    Yu Xia
    Yangyang Qi
    Yifan Chen
    Lingli Chen
    Peipei Zhang
    Yunyi Kong
    Yang Qu
    Zewei Wang
    Zhiyuan Lin
    Xiang Chen
    Zhuoyi Xiang
    Jiajun Wang
    Qi Bai
    Weijuan Zhang
    Yuanfeng Yang
    Jianming Guo
    Jiejie Xu
    Cancer Immunology, Immunotherapy, 2019, 68 : 731 - 741
12345